Privately-held US developer of healthcare therapies Nacuity Pharmaceuticals and Icelandic firm Arctic Therapeutics International have entered into an exclusive licensing agreement and strategic partnership for the development and commercialization of NPI-001 in Iceland for the treatment of hereditary cystatin C amyloid angiopathy (HCCAA).
HCCAA is an inherited, rare amyloid disease primarily seen in the Icelandic population that leads to paralysis, dementia and death in young adults.
NPI-001 is Nacuity’s proprietary, GMP-grade formulation of N-acetylcysteine amide (NACA) being developed for the treatment of a broad range of diseases associated with oxidative stress, including HCCAA, which is caused by a leucine to glutamine variant of human cystatin C (hCC). Clinical and in vitro data utilizing N-acetylcysteine and NACA for the treatment of HCCAA support a strong mechanistic rationale for NPI-001 as a potential effective therapy for the treatment of HCCAA.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze